Agree Sam, the voucher is used to fast track the product to market and/or to assist with previously spent R&D costs. I assume they apply for it if the P2b is successful. So trial funding is either through a CR or a partnership. We should see a share price boost with ODD for US and Europe, hopefully enough to clear AEF out of the picture..
The Rome Cohort, page-72
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.002(2.47%) |
Mkt cap ! $81.90M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.1¢ | 7.8¢ | $1.034M | 12.98M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 349999 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 305419 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |